September 3, 2019
Press release
EFPIA Japan(European Federation of Pharmaceutical Industries and Associations)

EFPIA Japan Patient Organization Support Program “PASE”
Third “PASE AWARD” winners decided
EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) has made its third
PASE AWARDs, selecting patient groups that particularly contribute to the evolution of Japan’s patientadvocacy and offering grants totaling 1.45 million yen. These grants have been made as part of “PASE(Patient Advocacy Support by EFPIA Japan (hereinafter, ’PASE’)”. For the third year, "patient group
activities for issues that have not yet been resolved in disease prevention, diagnosis, and treatment" wasselected as the application theme. Recruitment of patient organizations' action plans started in May. Thisyear the “Grand Award” has been given to two groups, and the “Honor Award” has been given to threegroups, from the total 15 groups that applied to this program by July 26.
PASE AWARD winning organizations
AwardAward winning
organization

GrandCancer Forum Yamanashi

Conduct “Survey of current status ofvaccination” with a view to preventing nondisease after hematopoietic stem celltransplantation.
• Conduct SE surveys associated with cancer
treatment

500,000

Lung one-step• Implement educational activities regarding
asbestos-derived lung cancer

150,000

Living with Cancer

Establish a site for the purpose of
networking for patient group such as cancer
and intractable diseases and care requiredby patients and families

150,000

Kirara (Breast cancer)

Award
Honor
Award
Honor
Award(JPY)• Conduct surveys with HCP to find unmet
needs for pediatric and adolescent patients.
• Focus group event based on survey results.

AwardHonor

Grant

HAEJ

Award
Grand

Overview of application/proposal

500,000

150,000EFPIA Japan
Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

Ole Mølskov Bech, Chairman of EFPIA Japan said: “I would like to express our appreciation to all theorganizations that participated in our PASE Awards program. Selecting the winners of the Grand Awardwas extremely challenging because the activities of all the patient organizations that applied were diversein terms of disease areas and scale. EFPIA Japan aims to realize a patient-centered medical environment
by supporting patient group activities to protect the environment where patients in Japan can continue toreceive better treatment.”＃＃＃About the EFPIA Japan Patient Organization Support Program “PASE”“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program establishedin 2017 with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE was conceived tofurther encourage patient group activities in Japan, and to support the healthcare environment surrounding
patients to evolve, so that it better reflects patients’ voices and patient needs. As part of PASE, EFPIA
Japan decided to conduct the PASE Awards, in which grants of 1.45 million yen this year will be awarded
to organizations that contribute to the evolution of patient advocacy (activities to protect patient rights).
(http://efpia.jp/link/1706_Notifcation_EFPIA_PASE_JP.pdf).
About the third “PASE Award”
New medicines that give patients hope for treatment are created by sustained investment in innovation1,and various new drugs approved in Japan have positively changed patients’ life. However, due to drastic
reform of the drug pricing system in recent years, there is concern that research and development ofmedicines in Japan is being delayed, which will lead to the re-emergence of the “drug lag”2. For the third
PASE Award, based on the potential impact on patients due to such environmental changes that year,"patient group activities to protect the environment so that patients can continue to receive better
treatment" was selected as an application theme. The third PASE Awards invited active patient groups withlegal entity status to submit plans between May 29 and July 26 to utilize the PASE grant in Japan. The
draft plans were reviewed and selection was based on four evaluation criteria: “Having a clear purpose asa patient group and clear goals with KPIs?”, “Showing concrete deliverables for achieving purpose in pastactivities”, “Having a specific implementation plan of activity for using grants (including how to use grants)”,“Being able to cooperate in disseminating the results of activities using grants (Allowing for posting on
EFPIA Japan website, notification and reporting on their own website)”. The two organizations that won
the Grand Award were each offered a grant of 500,000 yen and invited to attend the presentation ceremonyon 8 November last year. The three groups that won the Honor Award were offered a grant of 150,000 yen.

The third PASE Final Selection Committee Members
Dr. Ole Mølskov Bech (EFPIA, Chair)
Mr. Thorsten Poehl （EFPIA, Vice Chair）
Ms. Heike Prinz (EFPIA, Vice Chair)
Mr. Paul Lirette(EFPIA, Board member)

Ms. Kana Matsumura (Chair of Governance and Legal Committee)
Mr. Taro Kondo (Advisor, Tokyo Medical Association)
About the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan
EFPIA Japan, established in April 2002, represents 23 R&D-based European pharmaceutical companies
operating in the Japanese market. Combined sales from the EFPIA member companies account for
approximately 22% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “contributeto healthcare and patients in Japan through the rapid introduction of innovative medicines and vaccines”.
EFPIA Japan aims to strengthen communication with policymakers for the improvement of Japanese
healthcare.
About the European Federation of Pharmaceutical Industries and Associations (EFPIA)EFPIA, headquartered in Brussels, the capital of Belgium, represents the pharmaceutical industry
operating in Europe. Through its direct membership of 36 national associations and 39 leading
pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables ourmembers to innovate, discover, develop and deliver new therapies and vaccines for people as well as
contribute to the economy. Our vision is for a healthier future based on prevention, innovation, access tonew treatments and better outcomes for patients.
Details can be found below.
http://efpia.jp/English/index-e.html (EFPIA Japan)
http://www.efpia.eu (EFPIA)
Inquiries to:
Hitoshi Fujita, Public Relations Committee, EFPIA Japan
Novartis Pharma K.K.
1-23-1 Toranomon, Minato-ku, Tokyo 105-6333
TEL: 090-9837-4326
Mail: hitoshi.fujita@novartis.com
Miki Okada, Access Committee in charge of PASE, EFPIA Japan

GlaxoSmithKline K.K.
Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052
TEL : 070-3543-2224
Mail: miki.x.okada@gsk.com